ClinicalTrials.Veeva
Menu

Find clinical trials for Adenocarcinoma in Taipei City

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Carcinoma
Cancer
Pancreatic Cancer
Colorectal Cancer
Stomach Cancer
Prostatic Cancer
Esophageal Cancer

Adenocarcinoma trials near Taipei City, TWN:

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regim...

Enrolling
Gastric Cancer, Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Drug: Ramucirumab
Drug: Paclitaxel

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Taipei, Taiwan and 157 other locations

and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma...

Enrolling
Gastric Cancer
Drug: 5-Fluorouracil
Drug: AZD0901

Phase 2

AstraZeneca
AstraZeneca

Taipei, Taiwan and 42 other locations

Locations recently updated

and placebo in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).This study aims to explore whether blockade of Transforming Gr...

Active, not recruiting
Metastatic Pancreatic Ductal Adenocarcinoma
Drug: Nab-paclitaxel
Drug: Gemcitabine

Phase 3

Novartis
Novartis

Taipei, Taiwan and 113 other locations

The purpose of this study is to evaluate the efficacy of zolbetuximab plus capecitabine and oxaliplatin (CAPOX) compared with placebo plus CAPOX (as...

Active, not recruiting
Metastatic Gastric Adenocarcinoma or Cancer
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
Drug: oxaliplatin
Drug: capecitabine

Phase 3

Astellas
Astellas

Taipei, Taiwan and 164 other locations

of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma...

Enrolling
Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma
Drug: Evorpacept (ALX148)
Drug: Trastuzumab

Phase 2, Phase 3

ALX Oncology

Taipei, Taiwan and 54 other locations

The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall surviv...

Active, not recruiting
Metastatic Pancreatic Adenocarcinoma
Metastatic Pancreatic Cancer
Drug: nab-paclitaxel
Drug: gemcitabine

Phase 2

Astellas
Astellas

Taipei City, Taiwan and 137 other locations

chemotherapy with leucovorin, oxaliplatin, docetaxel and S-1 (LOTS) in patients with locally advanced gastric or gastroesophageal junction adenocarcinoma...

Enrolling
Gastric Adenocarcinoma
Gastric Cancer
Drug: leucovorin, oxaliplatin, docetaxel, S-1

Phase 2

National Cheng-Kung University

Taipei, Taiwan and 3 other locations

and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma...

Enrolling
Gastroesophageal Junction Cancer
Gastric Cancer
Drug: Apatinib
Drug: Ramucirumab+ paclitaxel

Phase 3

AstraZeneca
AstraZeneca

Taipei, Taiwan and 149 other locations

This study is being done to see if tucatinib with trastuzumab, ramucirumab and paclitaxel works better than ramucirumab and paclitaxel to treat HER2-...

Active, not recruiting
Esophageal Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Drug: paclitaxel
Drug: trastuzumab

Phase 2, Phase 3

Seagen
Seagen

Taipei, Taiwan and 47 other locations

generating, open-label, 2-Arm, non-randomized study, in patients with metastatic HER2/neu over-expressing gastric cancer or gastroesophageal adenocarcinomas...

Active, not recruiting
Gastroesophageal Junction Adenocarcinoma
Stomach Adenocarcinoma
Biological: Pembrolizumab
Biological: IMU-131

Phase 2

Imugene

Taipei, Taiwan and 6 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems